🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Denmark / NCT03160131
Recruiting Not applicable

Rehabilitation of Visual Function After Brain Injury

NCT03160131 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2017-08-01
Last updated
2024-12-09

Condition(s) studied

Stroke, IschemicBrain InjuriesStroke HemorrhagicTraumatic Brain Injury

Investigational drug(s) / intervention(s)

Neuro Vision Technology

Neuro Vision Technology: Training using Neuro Vision Technology

Study summary

In Denmark, about 120,000 people suffer from brain damage, of whom approx. 75,000 with brain damage after stroke. Serious and often lasting vision impairments affect 20% to 35% of people after stroke. Vision is the most important sense in humans, and even smaller permanent injuries can drastically reduce quality of life.

Vision impairments after brain damage inhibits rehabilitation and enhances other invalidating effects. Reduced vision results in impaired balance, increased risk of serious falls, increased support needs, reduced quality of life, and impaired ability to perform activities of daily living. Restoration of visual field impairments occur only to a small extent during the first month after brain damage, and therefore the time window for spontaneous improvements is very limited. Hence, brain-impaired persons with visual impairment will most likely experience chronically impaired vision already 4 weeks after brain injury and the need for visual compensatory rehabilitation is substantial.

Neuro Vision Technology (NVT) is an supervised training course where people with visual impairments are trained in compensatory techniques using special equipment. Through the NVT process, the individual's vision problems are carefully investigated and personal data is used to organize individual training sessions that practice the individual in coping with situations that cause problems in everyday life.

The purpose of this study is to investigate whether rehabilitation with NVT can cause significant and lasting improvement in functional capacity in persons with chronic visual impairments after brain injury. Improving eyesight is expected to increase both physical and mental functioning, thus improving the quality of life. Participants included in the project will be investigated in terms of both visual and mental functions, including quality of life, cognition and depression. Such an investigation has not been performed previously and can have a significant impact on vision rehabilitation both nationally and internationally.

Eligibility

Sex
ALL
Min age
14 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: * 14 years or older with brain injury. * Persons who experience significant vision impairment. * Eye sight 6/18 or better. * The time from symptoms onset to study inclusion is between 6 weeks and 9 months. Exclusion criteria: * Cognitive dysfunction. * Persons with anosognosia or severe neglect. * Inability to move independently at least 35 meters with or without assistance, including wheelchairs. * Inability to understand Danish or with communication disorders that prevent participation in tests. * Terminal disorder, other progressive disorder. * Significant abuse of alcohol or euphoric or narcotic drugs. * Serious disorders such as mental illness, especially severe depression. * New brain injury or other significant disorders emerging after study inclusion. * Impaired vision not due to brain damage, where the disorder is not considered to be permanent or where the field of vision does not cause significant disability.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Institute for the Blind and Partially Sighted (IBOS) Copenhagen Hellerup Recruiting

More University Hospital, Gentofte, Copenhagen trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03160131 on ClinicalTrials.gov ↗ ← All trials in Denmark